Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 10.33 USD 4.66% Market Closed
Market Cap: 556.1m USD

Prothena Corporation PLC
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Prothena Corporation PLC
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Prothena Corporation PLC
NASDAQ:PRTA
Interest Income Expense
$16.9m
CAGR 3-Years
87%
CAGR 5-Years
42%
CAGR 10-Years
67%
Alkermes Plc
NASDAQ:ALKS
Interest Income Expense
$39.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amarin Corporation PLC
NASDAQ:AMRN
Interest Income Expense
$11.6m
CAGR 3-Years
98%
CAGR 5-Years
27%
CAGR 10-Years
N/A
M
Mural Oncology PLC
NASDAQ:MURA
Interest Income Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Prothena Corporation PLC
Glance View

Market Cap
556.1m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
7.7 USD
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Prothena Corporation PLC's Interest Income Expense?
Interest Income Expense
16.9m USD

Based on the financial report for Sep 30, 2025, Prothena Corporation PLC's Interest Income Expense amounts to 16.9m USD.

What is Prothena Corporation PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
67%

Over the last year, the Interest Income Expense growth was -41%. The average annual Interest Income Expense growth rates for Prothena Corporation PLC have been 87% over the past three years , 42% over the past five years , and 67% over the past ten years .

Back to Top